Abstract: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided.

Abstract: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate.

Abstract: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate.

Abstract: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and at least one buffering agent.

Abstract: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate.

Abstract: The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and a kit for the preparation of a liquid oral pharmaceutical composition.

Abstract: The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H+,K+-ATPase proton pump inhibitor and a protein component; to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.

Abstract: The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H+K+-ATPase proton pump inhibitor and a protein component; to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.

Abstract: Disclosed herein are methods kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

Abstract: There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, is present in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form can be non-enteric coated and can be in the form of a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition of the present invention.

Abstract: A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

Abstract: Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

Abstract: A shelter/camper/tent assembly for use in a truck bed. The assembly includes a shell and a floor, each being independently and pivotally coupled to the front of the truck bed. A support structure spans between the sidewalls of the truck and operates to suspend the floor in the truck bed. An opening structure is spaced along and secured to the side of the shell and support structure to support the shell when in the open position. A floor extension is pivotally coupled to the rear edge of the floor allowing for an increase in floor surface area. An attachment mechanism for removably securing the floor to the shell allowing for the two members to pivot about the front of the truck bed in unison. A flexible tent section is secured between the shell and floor through the use of fastening devices.

Abstract: The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form; and a kit for the preparation of a liquid oral pharmaceutical composition.

Abstract: Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

Abstract: A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

Abstract: A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

Abstract: Disclosed herein are compositions and methods for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

Abstract: A shelter/camper/tent assembly for use in a truck bed. The assembly includes a shell and a floor, each being independently and pivotally coupled to the front of the truck bed. A support structure spans between the sidewalls of the truck and operates to suspend the floor in the truck bed. An opening structure is spaced along and secured to the side of the shell and support structure to support the shell when in the open position. A floor extension is pivotally coupled to the rear edge of the floor allowing for an increase in floor surface area. An attachment means for removably securing the floor to the shell allowing for the two members to pivot about the front of the truck bed in unison. A flexible tent section is secured between the shell and floor through the use of fastening devices.

Abstract: A pharmaceutical composition includes an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier comprising a bicarbonate salt of a Group IA metal. A method for treating and/or preventing gastrointestinal conditions by administering to a patient a pharmaceutical composition including an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal wherein the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal.